20
Mar
2023
Tag: Big Pharma / Specialty Pharma
13
Mar
2023
Bionest
Alzheimer’s Disease Update Part 2: The Importance of Amyloid and Its Clearance in AD
Could cellular waste management be key in treating Alzheimer's Disease? We explore this emerging field of research and potential for new AD drugs.
21
Feb
2023
Bionest
Alzheimer’s Disease Update Part 1: Lecanemab Provides New Support for the Amyloid Hypothesis
What will the recent accelerated approval of anti-amyloid lecanemab mean for Alzheimers patients, and will it overcome stringent CMS reimbursement policies?
19
Dec
2022
Bionest
COVID Vaccines Transition from Government Supply to Private Marketplace
What will be the impact of moving COVID vaccines to the private marketplace? We examine both the challenges and new opportunities for the companies.
5
Dec
2022
Bionest
Medicare Drug Price Negotiations: Potential Impacts
What impact will the Inflation Reduction Act have on pharma & biotech companies and what should they consider in their pipeline development plans?
21
Nov
2022
Bionest
Competitors Collaborate to Understand Shared DMD Adverse Event
Adverse responses to experimental gene therapies for Duchenne muscular dystrophy leads to unique collaboration between pharma competitors.
7
Nov
2022
Bionest
Down to the Wire: The Race Between Amgen and Mirati for KRAS-Inhibitor Approvals
Who is ahead in the race for KRAS-inhibitor approval? We explore the latest drug development updates for sotorasib and adagrasib.
10
Oct
2022
Bionest
Are the Blues Ending for Bluebird?
Gene therapy developer bluebird bio may be turning a corner, with recent FDA approvals for two of its rare disease therapeutics.
25
Apr
2022
Bionest
Biosimilars on the Rise, Spurring Company Integration and Consolidation
From one to 34: Biosimilars are on the rise. How will it affect the pharmaceutical market for companies and consumers?
28
Mar
2022